أعرض في EDS

Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma

التفاصيل البيبلوغرافية
العنوان: Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma
المؤلفون: Avivit Peer, Natalie Maimon, Maya Gottfried, Michael A. Carducci, Ben Boursi, Hans J. Hammers, Victoria J. Sinibaldi, Roberto Pili, Mario A. Eisenberger, Svetlana Kovel, Avishay Sella, Maya Ish-Shalom, Daniel Keizman, Henry Hayat, Raanan Berger
المصدر: European journal of cancer (Oxford, England : 1990). 48(7)
سنة النشر: 2011
مصطلحات موضوعية: Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, Indoles, Bone Neoplasms, urologic and male genital diseases, Drug Administration Schedule, Renal cell carcinoma, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Carcinoma, Sunitinib, Humans, Pyrroles, Progression-free survival, Carcinoma, Renal Cell, Aged, Retrospective Studies, Aged, 80 and over, Diphosphonates, Proportional hazards model, business.industry, Bone metastasis, Retrospective cohort study, Middle Aged, medicine.disease, female genital diseases and pregnancy complications, Kidney Neoplasms, Surgery, Treatment Outcome, Female, business, Progressive disease, medicine.drug
الوصف: Bisphosphonates are used to prevent skeletal events of bone metastases, and may exhibit antitumour effects. We aimed to evaluate whether bisphosphonates can bring a response rate (RR), progression free survival (PFS) and overall survival (OS) benefit to patients with bone metastasis from renal cell carcinoma (RCC) that is treated with sunitinib.We performed a multicentre retrospective study of patients with bone metastases from RCC that was treated with sunitinib. The effect of bisphosphonates on RR, PFS and OS was tested with adjustment for known prognostic factors using a chi-square test from contingency table and partial likelihood test from Cox regression model.Between 2004 and 2011, 209 patients with metastatic RCC were treated with sunitinib, 76 had bone metastases, 35 bisphosphonates users and 41 non-users. The groups of bisphosphonates users and non-users were balanced regarding known prognostic factors. Objective response was partial response/stable disease 86% (n = 30) versus 71% (n = 29), and progressive disease 14% (n = 5) versus 29% (n = 12) (p = 0.125, OR 2.48) in users versus non-users, respectively. Median PFS was 15 versus 5 months (HR = 0.55, p0.0001), and median OS was not reached (with a median follow-up time of 45 months) versus 14 months (HR = 0.4, p = 0.029), in favour of users. In multivariate analysis of the entire patient cohort (n = 76), factors associated with PFS were bisphosphonates use (HR = 0.58, p = 0.035), and pre-treatment neutrophil to lymphocyte ratio3 (HR = 3.5, p = 0.009). Factors associated with OS were bisphosphonates use (HR = 0.5, p = 0.008), elevated pre-treatment alkaline phosphatase (HR = 2.9, p = 0.003) and sunitinib induced HTN (HR = 0.63, p0.0001).Bisphosphonates may improve the RR, PFS and OS of sunitinib treatment in RCC with bone metastases.
تدمد: 1879-0852
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f8186de8b928be04ea225f8e6d85e28
https://pubmed.ncbi.nlm.nih.gov/22682018
حقوق: OPEN
رقم الأكسشن: edsair.doi.dedup.....7f8186de8b928be04ea225f8e6d85e28
قاعدة البيانات: OpenAIRE
الوصف
تدمد:18790852